Jubilant Life gets nod for Sodium Chloride injection

“This is the first ANDA approval in injectables received by the company. We have filed two injectables and one ophthalmic product as on March 31, 2016,” the company said.

NEW DELHI: Drug firm Jubilant Life Sciences on Wednesday said it has received approval from the US health regulator for its 0.9% Sodium Chloride injection, used for diluting or dissolving drugs, in the American market.

The company's subsidiary Jubilant HollisterStier LLC, has received abbreviated new drug application ( ANDA) approval for 0.9% Sodium Chloride injection USP, 3 ml and 10 ml vials, Jubilant Life Sciences said in a BSE filing. The company's injection is the generic version of Hospira Inc's Sodium Chloride 0.9% injection in plastic container, it added. The product is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, Jubilant Life Sciences said.

“This is the first ANDA approval in injectables received by the company. We have filed two injectables and one ophthalmic product as on March 31, 2016,” the company said.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

Related Companies

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Jubilant Life gets nod for Sodium Chloride injection
Text Size:AAA
Success
This article has been saved

*

+